

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10779532.str



chain nodes :

44 54

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
14-15 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26
27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41
38-39 39-40 40-41

exact/norm bonds :

7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14 14-15 15-16 17-18 17-21 18-19
 19-20 20-21 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29 29-30 30-31
 32-33 32-36 33-34 34-35 35-36 37-38 37-41 38-39 39-40 40-41

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :

G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:Atom 41:Atom 44:CLASS 45:CLASS 54:CLASS 55:CLASS

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d 14

L4 HAS NO ANSWERS

L1 SCR 1839

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

Structure diagram not available for display

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 14:43:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4749 TO ITERATE

21.1% PROCESSED, 1000 ITERATIONS

19 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 90848 TO 99112

PROJECTED ANSWERS: 1235 TO 2373

L5 19 SEA SSS SAM L3 AND L1 NOT L2

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10779532 (a).str



chain nodes :

44 53

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

chain bonds :

2-53

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
 14-15 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26
 27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41
 38-39 39-40 40-41

exact/norm bonds :

2-53 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14 14-15 15-16 17-18 17-21
 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29 29-30
 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41 38-39 39-40 40-41

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :

G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:Atom 41:Atom 44:CLASS 53:CLASS 54:CLASS

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> d 19

L9 HAS NO ANSWERS

L6 SCR 1839

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR

Structure diagram not available for display

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 AND L6 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 14:46:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1242 TO ITERATE

80.5% PROCESSED 1000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 22726 TO 26954

PROJECTED ANSWERS: 850 TO 1832

L10 50 SEA SSS SAM L8 AND L6 NOT L7

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10779532 (b).str



chain nodes :

44 53

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

chain bonds :

2-53 4-44

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
 14-15 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26
 27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41
 38-39 39-40 40-41

exact/norm bonds :

2-53 4-44 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14 14-15 15-16 17-18
 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29
 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41 38-39 39-40 40-41

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :

G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:Atom 41:Atom 44:CLASS 53:CLASS

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12

=> d l14

L14 HAS NO ANSWERS

L11 SCR 1839

L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L13 STR

Structure diagram not available for display

Structure attributes must be viewed using STN Express query preparation.

L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 14:50:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 275 TO ITERATE

100.0% PROCESSED 275 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4506 TO 6494

PROJECTED ANSWERS: 930 TO 1948

L15 50 SEA SSS SAM L13 AND L11 NOT L12

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L16 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L17 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10779532 (c).str

2-52 3-53 4-55 6-54

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
 14-15 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26
 27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41
 38-39 39-40 40-41

exact/norm bonds :

2-52 6-54 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14 14-15 15-16 17-18
 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29
 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41 38-39 39-40 40-41

exact bonds :

3-53 4-55

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :

G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:Atom 41:Atom 52:CLASS 53:CLASS 54:CLASS 55:CLASS

L18 STRUCTURE UPLOADED

=> que L18 AND L16 NOT L17

L19 QUE L18 AND L16 NOT L17

=> d l19

L19 HAS NO ANSWERS

L16 SCR 1839

L17 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L18 STR

Structure diagram not available for display

Structure attributes must be viewed using STN Express query preparation.

L19 QUE L18 AND L16 NOT L17

=> s l19 sss sam

SAMPLE SEARCH INITIATED 14:53:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 275 TO ITERATE

100.0% PROCESSED 275 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4506 TO 6494

10/779,532

PROJECTED ANSWERS: 9 TO 359

L20 9 SEA SSS SAM L18 AND L16 NOT L17

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L21 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L22 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10779532 (d).str



chain nodes :

52 53 55 56

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

chain bonds :

2-52 3-55 4-56 6-53

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
 14-15 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26
 27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41
 38-39 39-40 40-41

exact/norm bonds :

2-52 3-55 4-56 6-53 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14 14-15
 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26 27-28
 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41 38-39
 39-40 40-41

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :

G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G2:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:Atom 41:Atom 52:CLASS 53:CLASS 55:CLASS 56:CLASS

L23 STRUCTURE UPLOADED

=> que L23 AND L21 NOT L22

L24 QUE L23 AND L21 NOT L22

=> d 124

L24 HAS NO ANSWERS

L21 SCR 1839

L22 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L23 STR

Structure diagram not available for display

Structure attributes must be viewed using STN Express query preparation.

L24 QUE L23 AND L21 NOT L22

=> s 124 sss sam

SAMPLE SEARCH INITIATED 14:55:44 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 275 TO ITERATE

100.0% PROCESSED 275 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

10/779,532

PROJECTED ITERATIONS: 4506 TO 6494
PROJECTED ANSWERS: 9 TO 359

L25 9 SEA SSS SAM L23 AND L21 NOT L22

=> s 124 sss ful

FULL SEARCH INITIATED 14:55:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5700 TO ITERATE

100.0% PROCESSED 5700 ITERATIONS
SEARCH TIME: 00.00.01

359 ANSWERS

L26 359 SEA SSS FUL L23 AND L21 NOT L22

=> => s 126

L27 19 L26

=> d 127 1-19 bib,ab,hitstr

L27 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:701815 CAPLUS
 DN 141:185104
 TI Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
 IN Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar
 PA USA
 SO U.S. Pat. Appl. Publ., 107 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004167197	A1	20040826	US 2004-788220	20040226
WO 2004075852	A2	20040910	WO 2004-US5609	20040226
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004075857	A2	20040910	WO 2004-US5799	20040226
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-450529P P 20030226

AB This invention is directed generally to a method for treating a pathol. condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or "ACE inhibitor") for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compns. comprising a p38-kinase inhibitor, and more specifically to compns. comprising the above-described combinations.


IT 740845-73-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps., combinations, and methods for treating cardiovascular conditions and other associated conditions)

RN 740845-73-2 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[1-(1,3-dihydro-5-isobenzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:287841 CAPLUS

DN 140:321349

TI Preparation of pyrazole derivatives as p38 MAP kinase inhibitors and cytokine production inhibitors

IN Hagihara, Masahiko; Shibakawa, Nobuhiko; Nishihara, Masamichi; Shirai, Toshiyuki; Shimizu, Motohisa; Hasegawa, Tohru; Tokunaga, Yasunori; Suzuki, Naoto; Wada, Yukinori

PA Ube Industries, Ltd., Japan

SO PCT Int. Appl., 276 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004029043	A1	20040408	WO 2003-JP12254	20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI JP 2002-279385	A	20020925		

OS MARPAT 140:321349


AB The title compds. I [R1 is optionally substituted phenyl; R2 is H, halogeno, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, or substituted amino; Q is CH or N; R3 is H, alkyl, or amino; and R4 is a group represented by the general formula Q1, etc.; R7 is H or alkyl; R8 is H, alkyl, or substituted amino; R9 is H or alkyl] are prepared Compds. of this invention in vitro showed IC50 values of 0.2 nM to 8.8 nM against p38 MAP kinase. Formulations are given.

IT 677318-82-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

RN 677318-82-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-[3-(trifluoromethyl)-1,2,4-triazolo[4,3-b]pyridazin-6-yl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




IT 677317-98-5P 677318-04-6P 677318-06-8P
 677318-08-0P 677318-10-4P 677318-12-6P
 677318-14-8P 677318-16-0P 677318-18-2P
 677318-20-6P 677318-22-8P 677318-26-2P
 677318-28-4P 677318-30-8P 677318-32-0P
 677318-34-2P 677318-36-4P 677318-38-6P
 677318-41-1P 677318-52-4P 677318-60-4P
 677318-62-6P 677318-64-8P 677318-66-0P
 677318-68-2P 677318-70-6P 677318-72-8P
 677318-74-0P 677318-76-2P 677318-78-4P
 677318-80-8P 677318-84-2P 677318-86-4P
 677318-92-2P 677318-94-4P 677318-98-8P
 677319-00-5P 677319-02-7P 677319-04-9P
 677319-08-3P 677319-18-5P 677319-20-9P
 677319-22-1P 677319-24-3P 677319-26-5P
 677319-28-7P 677319-30-1P 677319-34-5P
 677319-36-7P 677319-38-9P 677319-40-3P
 677319-42-5P 677319-44-7P 677319-46-9P
 677319-48-1P 677319-50-5P 677319-52-7P
 677319-54-9P 677319-56-1P 677319-58-3P
 677319-60-7P 677319-62-9P 677319-64-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)


RN 677317-98-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-04-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-06-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-(methyamino)-4-pyridinyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-08-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-[2-(ethylamino)-4-pyridinyl]-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-10-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-12-6 CAPLUS

CN Acetamide, N-[4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677318-14-8 CAPLUS

CN Carbamic acid, [4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 677318-16-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-5-methyl- (9CI) (CA INDEX NAME)




RN 677318-18-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 677318-20-6 CAPLUS

CN 3(2H)-Pyridazinone, 4-amino-6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-22-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 677318-26-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-28-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-chlorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-30-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3,4-difluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-32-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-34-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(2-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-36-4 CAPLUS

CN 3(2H)-Pyridazinone, 6-[3-(2-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-38-6 CAPLUS

CN Acetamide, N-[4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677318-41-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677318-52-4 CAPLUS

CN 2-Pyridinamine, 4-[3-phenyl-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677318-60-4 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677318-62-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 677318-64-8 CAPLUS

CN 2-Pyridinamine, N-ethyl-4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677318-66-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 677318-68-2 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 677318-70-6 CAPLUS

CN Acetamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677318-72-8 CAPLUS

CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 677318-74-0 CAPLUS

CN Methanesulfonamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677318-76-2 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 677318-78-4 CAPLUS

CN Benzamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677318-80-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677318-84-2 CAPLUS

CN 1,2,4-Triazolo[4,3-b]pyridazin-3-amine, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 677318-86-4 CAPLUS

CN Acetamide, N-[6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-1,2,4-triazolo[4,3-b]pyridazin-3-yl]- (9CI) (CA INDEX NAME)




RN 677318-92-2 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677318-94-4 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677318-98-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(3,4-difluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677319-00-5 CAPLUS

CN 2-Pyridinamine, 4-[1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677319-02-7 CAPLUS

CN 2-Pyridinamine, 4-[3-(2-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677319-04-9 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677319-08-3 CAPLUS

CN Cyclopentanecarboxamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677319-18-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-phenyl-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-20-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-22-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-24-3 CAPLUS

CN Acetamide, N-[4-[3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677319-26-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 677319-28-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 677319-30-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-2-methyl- (9CI) (CA INDEX NAME)




RN 677319-34-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-36-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-38-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3,4-difluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-40-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-42-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(2-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-44-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[3-(2-fluorophenyl)-4-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 677319-46-9 CAPLUS

CN Acetamide, N-[4-[3-(2-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677319-48-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3-phenyl-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677319-50-5 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 677319-52-7 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3-(2-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-54-9 CAPLUS

CN 2-Pyridinamine, 4-[1-(7,8-dihydro-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 677319-56-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 677318-04-6
CMF C18 H13 F N6 O



CM 2


CRN 98-11-3
CMF C6 H6 O3 S



RN 677319-58-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]-, sulfate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 677318-10-4
CMF C20 H14 F4 N6 O



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 677319-60-7 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 677318-60-4


CMF C19 H13 F N8



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 677319-62-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 677319-20-9


CMF C18 H15 F N6 O



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 677319-64-1 CAPLUS

CN Acetamide, N-[4-[3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 677319-72-1P 677319-74-3P 677319-84-5P
 677320-01-3P 677320-03-5P 677320-07-9P
 677320-09-1P 677320-13-7P 677320-15-9P
 677320-21-7P 677320-23-9P 677320-27-3P
 677320-29-5P 677320-35-3P 677320-37-5P
 677320-43-3P 677320-45-5P 677320-49-9P
 677320-51-3P 677320-53-5P 677320-55-7P
 677320-57-9P 677320-59-1P 677320-61-5P
 677320-63-7P 677320-66-0P 677320-74-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)


RN 677319-72-1 CAPLUS

CN Carbamic acid, [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677319-74-3 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridazinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677319-84-5 CAPLUS

CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-01-3 CAPLUS

CN Carbamic acid, [4-(3-phenyl-1H-pyrazol-4-yl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-03-5 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-phenyl-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-07-9 CAPLUS

CN Carbamic acid, [4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-09-1 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-(3-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-13-7 CAPLUS

CN Carbamic acid, [4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-15-9 CAPLUS

CN Carbamic acid, [4-[3-(4-chlorophenyl)-1-(6-chloro-3-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-21-7 CAPLUS

CN Carbamic acid, [4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-23-9 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-27-3 CAPLUS

CN Carbamic acid, [4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-29-5 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-35-3 CAPLUS

CN Carbamic acid, [4-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-37-5 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-43-3 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-4-methyl-3-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-45-5 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-5-methyl-3-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-49-9 CAPLUS

CN Carbamic acid, [4-[3-phenyl-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-51-3 CAPLUS

CN Carbamic acid, [4-[3-(3-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-53-5 CAPLUS

CN Carbamic acid, [4-[3-(4-chlorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-55-7 CAPLUS

CN Carbamic acid, [4-[3-(3,4-difluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-57-9 CAPLUS

CN Carbamic acid, [4-[1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-59-1 CAPLUS

CN Carbamic acid, [4-[3-(2-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 677320-61-5 CAPLUS

CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-63-7 CAPLUS


CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-[3-(trifluoromethyl)-1,2,4-triazolo[4,3-b]pyridazin-6-yl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-66-0 CAPLUS


CN Carbamic acid, [4-[1-(3-amino-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)



RN 677320-74-0 CAPLUS

CN Carbamic acid, [4-[1-[3-(acetylamino)-1,2,4-triazolo[4,3-b]pyridazin-6-yl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:177876 CAPLUS

DN 140:235698

TI Preparation of 4-[4-(4-fluorophenyl)-isoxazol-3-yl]pyridines as immunomodulators

IN Laufer, Stefan; Striegel, Hans-Guenter; Tollmann, Karola; Albrecht, Wolfgang

PA Merckle G.m.b.H. Chem.-Pharm. Fabrik, Germany

SO Ger. Offen., 22 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10237883	A1	20040304	DE 2002-10237883	20020819
	WO 2004017968	A1	20040304	WO 2003-EP9191	20030819
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	DE 2002-10237883	A	20020819		

OS MARPAT 140:235698

AB Title compds. I [R1 = H, alkyl, aromatic; R2, R3 = aromatic heterocyclic (sic)] and their pharmaceutically acceptable salts were prepared For example, condensation of oxime II, e.g., prepared from 4-fluorophenylacetic acid in 2-steps, and acetic acid Et ester afforded isoxazole III. In p38 MAP kinase inhibition assays, 11-examples of compds. I exhibited IC50 values ranging from 0.4-6.75 x 10⁻⁵ M, e.g., the IC50 value of isoxazole III was 6.75 x 10⁻⁵ M. Compds. I are claimed to possess immune modulating and/or cytokine release inhibiting effects.


IT **666861-63-8P**, N-[4-[4-(4-Fluorophenyl)-3-pyridin-4-ylisoxazol-5-yl]pyridin-2-yl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fluorophenylisoxazolpyridines as immunomodulators)

RN 666861-63-8 CAPLUS

CN Acetamide, N-[4-[4-(4-fluorophenyl)-3-(4-pyridinyl)-5-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:874966 CAPLUS
 DN 139:364918

TI Preparation of isoxazole derivatives as inhibitors of Src and other protein kinases

IN Harrington, Edmund

PA USA

SO U.S. Pat. Appl. Publ., 22 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

Common Inv.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003207873	A1	20031106	US 2002-119890	20020410
PRAI	US 2002-119890		20020410		
OS	MARPAT 139:364918				

Abn

AB Isoxazole derivs. of formula I [X = alkylene, O, S, (substituted) NH, SO₂, etc.; A = N, (substituted) CH; R = H, alkyl, aryl, etc.; R₁ = H, alkyl, aryl, acyl, etc.; R₂ = H, alkyl, CH₂OH, CHO, CH₂NH₂, aryl, etc.] are prepared These compds. are inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. Thus, II was prepared from 3-(bis(methylthio)methylene)pentane-2,4-dione, DMF di-Me acetal and 3,5-dimethoxyphenyl guanidine. Many of the compds. tested for inhibition of Src had IC₅₀ < 1 μM.


IT 473445-73-7P 473445-74-8P 473445-75-9P
 473445-76-0P 473445-77-1P 473445-78-2P
 473445-79-3P 473445-88-4P 473445-91-9P
 473445-97-5P 473445-98-6P 473446-00-3P
 473446-02-5P 473446-03-6P 473446-09-2P
 473446-11-6P 473446-12-7P 473446-77-4P
 473446-79-6P 473446-81-0P 473446-83-2P
 473447-15-3P 473447-17-5P 473447-19-7P
 473447-21-1P 473447-23-3P 473447-25-5P
 473447-45-9P 473447-46-0P 473447-47-1P
 473447-48-2P 473447-49-3P 473447-50-6P
 473447-72-2P 473448-01-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of isoxazole derivs. as inhibitors of Src, Lck, and JNK3 protein kinases)

RN 473445-73-7 CAPLUS


CN Benzonitrile, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473445-74-8 CAPLUS
 CN Benzoic acid, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473445-75-9 CAPLUS
 CN 2-Pyridinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-76-0 CAPLUS
 CN 2-Pyridinamine, N-(4-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473445-77-1 CAPLUS
 CN Ethanone, 1-[4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 473445-78-2 CAPLUS

CN Methanone, [4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 473445-79-3 CAPLUS

CN Benzamide, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473445-88-4 CAPLUS

CN 2-Pyridinamine, 4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473445-91-9 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473445-97-5 CAPLUS

CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473445-98-6 CAPLUS

CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473446-00-3 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473446-02-5 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI)
(CA INDEX NAME)




RN 473446-03-6 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473446-09-2 CAPLUS


CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473446-11-6 CAPLUS
 CN Benzonitrile, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473446-12-7 CAPLUS
 CN Benzonitrile, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-77-4 CAPLUS
 CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 473446-79-6 CAPLUS
 CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 473446-81-0 CAPLUS

CN Acetamide, N-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 473446-83-2 CAPLUS

CN 1,3-Benzenediamine, N-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 473447-15-3 CAPLUS

CN Benzenepropanoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473447-17-5 CAPLUS

CN Benzeneacetic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-19-7 CAPLUS


CN Benzenemethanol, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-21-1 CAPLUS


CN L-Valine, N-[3-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473447-23-3 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 473447-25-5 CAPLUS

CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473447-45-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-46-0 CAPLUS

CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-47-1 CAPLUS

CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-48-2 CAPLUS

CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-49-3 CAPLUS

CN Glycine, N-methyl-N-[[3-(methylthio)-4-[2-(phenylamino)-4-pyridinyl]-5-isoxazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 473447-50-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-5-(1-piperazinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME).




RN 473447-72-2 CAPLUS

CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473448-01-0 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methanesulfonyl)-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)



L27 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:590836 CAPLUS
 DN 139:149624
 TI Preparation of 1,4-diarylpyrazole inhibitors of src and other protein kinases
 IN Young, Choon Moon
 PA USA
 SO U.S. Pat. Appl. Publ., 35 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003144309	A1	20030731	US 2002-146984	20020516
PRAI	US 2002-146984		20020516		
OS	MARPAT 139:149624				

AB Title compds. I [G = XR, XAr; X = alkylidene wherein one or two non-adjacent methylene units of X are replaced by O, amino, S, CO, etc.; A = N, CR; R = H, aliphatic, etc.; Ar = (un)substituted 5-6 membered (un)saturated

monocyclic ring, etc.; R1 = TnR, TnAr; n = 0-1; T = CO, CO2, COCO, etc.; R2 = H, Ar, aliphatic; R3 = R, Ar] are prepared For instance, 3-(bis(methylsulfanyl)methylene)pentane-2,4-dione (preparation given) is condensed with (pyridin-2-yl)hydrazine to give 1-[5-methyl-3-(methylsulfanyl)-1-(pyridin-2-yl)-1H-pyrazole-4-yl]ethanone. This intermediate is reacted with DMFDMA (reflux) and the resulting β -amino enone condensed with N-(3-benzyloxyphenyl)guanidine to give II. Many of the compds. have $K_i \leq 1 \mu\text{M}$ for src kinase. I are inhibitors of protein kinase, particularly inhibitors of src mammalian protein kinase involved in cell proliferation, cell death in response to extracellular stimuli.


IT 475574-61-9P 475574-62-0P 475574-81-3P
 475574-82-4P 475574-83-5P 475574-84-6P
 475574-85-7P 475574-86-8P 475575-06-5P
 475575-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-phenyl-4-pyrimidinyl-substituted pyrazole inhibitors of src and other protein kinases)


RN 475574-61-9 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 475574-62-0 CAPLUS

CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-81-3 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-82-4 CAPLUS

CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-83-5 CAPLUS

CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-84-6 CAPLUS

CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-85-7 CAPLUS

CN Glycine, N-methyl-N-[[3-(methylthio)-1-phenyl-4-[2-(phenylamino)-4-pyridinyl]-1H-pyrazol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 475574-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-1-phenyl-5-(1-piperazinylmethyl)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-06-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-23-6 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



L27 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:150531 CAPLUS

DN 138:187765

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew
 J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi

PA G.D. Searle and Co., USA

SO U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6525059	B1	20030225	US 2000-513351	20000224
	US 6514977	B1	20030204	US 1998-196623	19981120
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-196623	A2	19981120		
	WO 1999-US26007	A1	19991117		
	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		

OS MARPAT 138:187765

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 μ M and inhibited tumor necrosis factor α (TNF α) and interleukin 1 β (IL-1 β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 μ M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF α .

IT 216504-83-5P 216504-84-6P 216504-85-7P
 216504-86-8P 216504-87-9P 216504-88-0P
 216505-92-9P 216506-33-1P 216506-39-7P
 216506-40-0P 216506-41-1P 216506-42-2P
 216506-64-8P 216506-65-9P 216506-66-0P
 216506-67-1P 216506-72-8P 216506-73-9P
 216506-82-0P 216506-83-1P 216506-85-3P
 216506-87-5P 216506-93-3P 216506-95-5P


216506-96-6P 216506-98-8P 216506-99-9P
 216507-01-6P 216507-03-8P 216507-04-9P
 216507-06-1P 271574-67-5P 271574-81-3P
 271574-82-4P 271574-83-5P 271574-84-6P
 271574-85-7P 271574-86-8P 271574-87-9P
 271574-88-0P 271574-89-1P 271574-90-4P
 271574-91-5P 271574-93-7P 271574-96-0P
 271574-97-1P 271574-98-2P 271575-03-2P
 271575-04-3P 271575-05-4P 271575-07-6P
 271575-09-8P 271575-10-1P 271575-11-2P
 271575-12-3P 271575-21-4P 271575-22-5P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 216504-83-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)




RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)



RN 216504-85-7 CAPLUS



CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)




RN 216504-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-87-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-88-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-92-9 CAPLUS
 CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 3 HCl

RN 216506-33-1 CAPLUS
 CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 216506-39-7 CAPLUS

CN 2-(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI)
(CA INDEX NAME)




RN 216506-40-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 216506-41-1 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 216506-64-8 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216506-65-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-66-0 CAPLUS

CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-67-1 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-72-8 CAPLUS

CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-73-9 CAPLUS

CN 2-Pyridinamine, N-[(3-(4-fluorophenyl)methyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-82-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 216506-83-1 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 216506-85-3 CAPLUS

CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-87-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 216506-93-3 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-95-5 CAPLUS

CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-96-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 216506-98-8 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-99-9 CAPLUS

CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 216507-01-6 CAPLUS

CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 216507-03-8 CAPLUS

CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 216507-04-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS



CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 271574-67-5 CAPLUS

CN Carbamic acid, [3-[[5-(4-chlorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 271574-81-3 CAPLUS
 CN 1-Piperazinepropanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 271574-80-2
 CMF C22 H27 F N6




CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.




RN 271574-82-4 CAPLUS
CN 1,2-Propanediol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 271574-83-5 CAPLUS
CN 1,3-Propanediamine, N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 271574-84-6 CAPLUS
CN 1,3-Propanediamine, N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 271574-85-7 CAPLUS

CN 2-Pyridinamine, N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 271574-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 271574-87-9 CAPLUS

CN 2-Pyridinamine, N-[(1-ethyl-4-piperidinyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-88-0 CAPLUS


CN 1,2-Ethanediamine, N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 271574-89-1 CAPLUS


CN 1-Pentanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271574-90-4 CAPLUS

CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 271574-91-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 271574-93-7 CAPLUS


CN 2-Pyridinamine, N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-96-0 CAPLUS

CN Benzenepropanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271574-97-1 CAPLUS

CN Benzenethanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271574-98-2 CAPLUS

CN Benzenepropanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271575-03-2 CAPLUS


CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-04-3 CAPLUS


CN 1,4-Pentanediamine, N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 271575-05-4 CAPLUS


CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271575-07-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(2-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 271575-09-8 CAPLUS

CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-10-1 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-11-2 CAPLUS


CN Benzeneethanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-12-3 CAPLUS


CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-21-4 CAPLUS


CN Cyclohexanol, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 271575-22-5 CAPLUS

CN Cyclohexanone, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:92403 CAPLUS

DN 138:137307

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew
 J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi

PA G.D. Searle and Co., USA

SO U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6514977	B1	20030204	US 1998-196623	19981120
	CA 2351725	AA	20000602	CA 1999-2351725	19991117
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	EP 1144403	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200102001	T2	20011221	TR 2001-200102001	19991117
	BR 9915420	A	20020122	BR 1999-15420	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	NZ 512344	A	20031128	NZ 1999-512344	19991117
	AU 774262	B2	20040624	AU 2000-21454	19991117
	AT 278685	E	20041015	AT 1999-965756	19991117
	EP 1500657	A1	20050126	EP 2004-23186	19991117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6525059	B1	20030225	US 2000-513351	20000224
	ZA 2001003882	A	20021014	ZA 2001-3882	20010514
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
	US 6423713	B1	20020723	US 2001-918481	20010731
	US 6617324	B1	20030909	US 2002-114297	20020402
	US 2004176433	A1	20040909	US 2003-374781	20030225
PRAI	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		
	US 1998-196623	A	19981120		
	EP 1999-965756	A3	19991117		
	WO 1999-US26007	W	19991117		
	US 2001-918481	A3	20010731		

Same as #16

US 2002-114297 A3 20020402

OS MARPAT 138:137307


AB Title compds. [I; R1 = H, OH, NH₂, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R₃CH₂COMe (R₃ = 4-pyridinyl) was condensed with 3,4-F(MeO)C₆H₃CHO to give the butenone (80%), which was cyclocondensed with TsNHNH₂ to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC₅₀ of 4.6 μ M and inhibited tumor necrosis factor α (TNF α) and interleukin 1 β (IL-1 β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC₅₀ of 0.5 μ M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF α .

IT 216504-83-5P 216504-84-6P 216504-85-7P
 216504-86-8P 216504-87-9P 216504-88-0P
 216505-92-9P 216506-33-1P 216506-39-7P
 216506-40-0P 216506-41-1P 216506-42-2P
 216506-64-8P 216506-65-9P 216506-66-0P
 216506-67-1P 216506-72-8P 216506-73-9P
 216506-82-0P 216506-83-1P 216506-85-3P
 216506-87-5P 216506-93-3P 216506-95-5P
 216506-96-6P 216506-98-8P 216506-99-9P
 216507-01-6P 216507-03-8P 216507-04-9P
 216507-06-1P 271574-67-5P 271574-81-3P
 271574-82-4P 271574-83-5P 271574-84-6P
 271574-85-7P 271574-86-8P 271574-87-9P
 271574-88-0P 271574-89-1P 271574-90-4P
 271574-91-5P 271574-93-7P 271574-96-0P
 271574-97-1P 271574-98-2P 271575-03-2P
 271575-04-3P 271575-05-4P 271575-07-6P
 271575-09-8P 271575-10-1P 271575-11-2P
 271575-12-3P 271575-21-4P 271575-22-5P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-83-5 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)



RN 216504-84-6 .CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)



RN 216504-85-7 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)


RN 216504-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-87-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-88-0 CAPLUS
 CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-92-9 CAPLUS
 CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 3 HCl

RN 216506-33-1 CAPLUS
 CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
 (9CI) (CA INDEX NAME)




RN 216506-39-7 CAPLUS
 CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI)


(CA INDEX NAME)



RN 216506-40-0 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)

RN 216506-41-1 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)-
(9CI) (CA INDEX NAME)

RN 216506-42-2 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA
INDEX NAME)



RN 216506-64-8 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216506-65-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-66-0 CAPLUS

CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-67-1 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-72-8 CAPLUS

CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-73-9 CAPLUS

CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-82-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 216506-83-1 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 216506-85-3 CAPLUS

CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-87-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 216506-93-3 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-95-5 CAPLUS


CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-96-6 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl-
(9CI) (CA INDEX NAME)

RN 216506-98-8 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-
4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


RN 216506-99-9 CAPLUS

CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 216507-01-6 CAPLUS

CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 216507-03-8 CAPLUS

CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 216507-04-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS



CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 271574-67-5 CAPLUS

CN Carbamic acid, [3-[[5-(4-chlorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 271574-81-3 CAPLUS
 CN 1-Piperazinepropanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 271574-80-2
 CMF C22 H27 F N6




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 271574-82-4 CAPLUS

CN 1,2-Propanediol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 271574-83-5 CAPLUS

CN 1,3-Propanediamine, N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 271574-84-6 CAPLUS

CN 1,3-Propanediamine, N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 271574-85-7 CAPLUS

CN 2-Pyridinamine, N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 271574-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 271574-87-9 CAPLUS

CN 2-Pyridinamine, N-[(1-ethyl-4-piperidinyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-88-0 CAPLUS


CN 1,2-Ethanediamine, N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 271574-89-1 CAPLUS


CN 1-Pentanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271574-90-4 CAPLUS

CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 271574-91-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 271574-93-7 CAPLUS


CN 2-Pyridinamine, N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-96-0 CAPLUS

CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271574-97-1 CAPLUS

CN Benzenethanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271574-98-2 CAPLUS

CN Benzenepropanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271575-03-2 CAPLUS


CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-04-3 CAPLUS


CN 1,4-Pentanediamine, N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 271575-05-4 CAPLUS


CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271575-07-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(2-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 271575-09-8 CAPLUS

CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-10-1 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-11-2 CAPLUS


CN Benzeneethanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-12-3 CAPLUS


CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-21-4 CAPLUS


CN Cyclohexanol, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 271575-22-5 CAPLUS

CN Cyclohexanone, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN.

AN 2002:888716 CAPLUS

DN 137:384853

TI Preparation of pyrazolyl pyridinamines and pyrimidinamines as inhibitors of Src and other protein kinases

IN Moon, Young-Choon

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092573	A2	20021121	WO 2002-US15606	20020516
	WO 2002092573	A3	20040122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1404669	A2	20040407	EP 2002-769762	20020516
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004534754	T2	20041118	JP 2002-589459	20020516
PRAI	WO 2002-US15606	W	20020516		

OS MARPAT 137:384853

AB Title compds. I [wherein G = XR or XAr; X = independently alkylidene wherein 1-2 non-adjacent methylene units are independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO₂, NRSO₂, SO₂NR, or NRSO₂NR; A = N or CR; R = H or (un)substituted aliphatic group; or NR₂ = heterocyclyl; Ar = (un)substituted 5-6 membered monocyclic ring with 0-3 heteroatoms or 8-10 membered bicyclic ring with 0-4 heteroatoms; R₁ = TnR or TnAr; n = 0-1; T = CO, CO₂, COCO, COCH₂CO, CONR, SO₂, or SO₂NR; R₂ = H, Ar, or (un)substituted aliphatic group; R₃ = R or Ar; or pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli (no data). For example, 3-dimethylamino-1-[5-methyl-3-methylsulfanyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]propenone was coupled with N-(3-benzoyloxyphenyl)guanidine in MeOH to give II (40%). I and compns. containing I are useful in the treatment and prevention of various inflammatory, autoimmune, destructive bone, proliferative, infectious, neurodegenerative, allergic, and cardiac disorders and diseases (no data).

IT **475574-61-9P**, N-(3-Pyridyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyridin-2-yl]amine **475574-62-0P**, N-(6-Methoxy-3-pyridyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyridin-2-yl]amine **475574-81-3P**, N-Phenyl-N-[4-[5-(4-morpholinylmethyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-82-4P**, N-Phenyl-N-[4-[5-((dimethylamino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-83-5P**, N-Phenyl-N-[4-[5-((diethylamino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-


Common
Assigneeno
US
appn

pyridyl]amine **475574-84-6P**, N-Phenyl-N-[4-[5-
 (((methyl)(phenylmethyl)amino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-85-7P**, N-Phenyl-N-[4-[5-
 (((methoxycarbonyl)methyl)(methyl)amino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-86-8P**,
 N-Phenyl-N-[4-[5-(1-piperazinylmethyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475575-06-5P**, N-Phenyl-N-[4-[5-methyl-3-(ethylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine
475575-23-6P, N-Phenyl-N-[4-[5-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyridinyl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Src protein kinase inhibitor; preparation of pyrazolyl pyridinamines and pyrimidinamine inhibitors of protein kinases using condensation, cyclization, and substitution reactions)


RN 475574-61-9 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 475574-62-0 CAPLUS

CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-81-3 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-82-4 CAPLUS

CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-83-5 CAPLUS

CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-84-6 CAPLUS

CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-85-7 CAPLUS

CN Glycine, N-methyl-N-[[3-(methylthio)-1-phenyl-4-[2-(phenylamino)-4-pyridinyl]-1H-pyrazol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 475574-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-1-phenyl-5-(1-piperazinylmethyl)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-06-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-23-6 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylethylamino)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



L27 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:814127 CAPLUS
 DN 137:325409
 TI Preparation of isoxazole derivatives as inhibitors of Src and other
 protein kinases
 IN Harrington, Edmund
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083668	A1	20021024	WO 2002-US11609	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443234	AA	20021024	CA 2002-2443234	20020410
EP 1377572	A1	20040107	EP 2002-731356	20020410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500261	T2	20050106	JP 2002-581423	20020410
PRAI US 2001-282935P	P	20010410		
WO 2002-US11609	W	20020410		


OS MARPAT 137:325409
 AB Isoxazole derivs. of formula I [X = alkylene, O, S, (substituted) NH, SO₂, etc.; A = N, (substituted) CH; R = H, alkyl, aryl, etc.; R₁ = H, alkyl, aryl, acyl, etc.; R₂ = H, alkyl, CH₂OH, CHO, CH₂NH₂, aryl, etc.] are prepared. These compds. are inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. Thus, II was prepared from 3-(bis(methylthio)methylene)pentane-2,4-dione, DMF di-Me acetal and 3,5-dimethoxyphenyl guanidine. Many of the compds. tested for inhibition of Src had IC₅₀ < 1 μ M.

IT 473445-73-7P 473445-74-8P 473445-75-9P
 473445-76-0P 473445-77-1P 473445-78-2P
 473445-79-3P 473445-88-4P 473445-91-9P
 473445-97-5P 473445-98-6P 473446-00-3P
 473446-02-5P 473446-03-6P 473446-09-2P
 473446-11-6P 473446-12-7P 473446-77-4P
 473446-79-6P 473446-81-0P 473446-83-2P
 473447-15-3P 473447-17-5P 473447-19-7P
 473447-21-1P 473447-23-3P 473447-25-5P
 473447-45-9P 473447-46-0P 473447-47-1P
 473447-48-2P 473447-49-3P 473447-50-6P
 473447-72-2P 473448-01-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoxazole derivs. as inhibitors of Src, Lck, and JNK3)


protein kinases)
 RN 473445-73-7 CAPLUS
 CN Benzonitrile, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473445-74-8 CAPLUS
 CN Benzoic acid, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-75-9 CAPLUS
 CN 2-Pyridinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473445-76-0 CAPLUS
 CN 2-Pyridinamine, N-(4-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473445-77-1 CAPLUS

CN Ethanone, 1-[4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 473445-78-2 CAPLUS

CN Methanone, [4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 473445-79-3 CAPLUS


CN Benzamide, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-88-4 CAPLUS


CN 2-Pyridinamine, 4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI)

(CA INDEX NAME)




RN 473445-91-9 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473445-97-5 CAPLUS

CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473445-98-6 CAPLUS

CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473446-00-3 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473446-02-5 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI)
(CA INDEX NAME)




RN 473446-03-6 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473446-09-2 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473446-11-6 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473446-12-7 CAPLUS

CN Benzonitrile, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473446-77-4 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 473446-79-6 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 473446-81-0 CAPLUS

CN Acetamide, N-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 473446-83-2 CAPLUS

CN 1,3-Benzenediamine, N-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 473447-15-3 CAPLUS

CN Benzenepropanoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 473447-17-5 CAPLUS

CN Benzeneacetic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-19-7 CAPLUS


CN Benzenemethanol, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-21-1 CAPLUS


CN L-Valine, N-[3-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473447-23-3 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 473447-25-5 CAPLUS

CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 473447-45-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-46-0 CAPLUS

CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-47-1 CAPLUS

CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-48-2 CAPLUS

CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-49-3 CAPLUS

CN Glycine, N-methyl-N-[[3-(methylthio)-4-[2-(phenylamino)-4-pyridinyl]-5-isoxazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 473447-50-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(methylthio)-5-(1-piperazinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 473447-72-2 CAPLUS

CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI)
(CA INDEX NAME)



RN 473448-01-0 CAPLUS

CN 2-Pyridinamine, 4-[5-methyl-3-(methylsulfonyl)-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE. FORMAT

L27 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:716268 CAPLUS
 DN 137:247688
 TI Preparation of pyridinylpyrazoles for the treatment of COPD
 IN Alonso-Alija, Cristina; Goldmann, Siegfried; Dodd, Sara; Fitzgerald, Mary;
 Nash, Kevin
 PA Bayer Aktiengesellschaft, Germany
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072571	A2	20020919	WO 2002-EP2316	20020304
	WO 2002072571	A3	20031030		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	GB 2373245	A1	20020918	GB 2001-6061	20010312
PRAI	GB 2001-6061	A	20010312		

OS MARPAT 137:247688

AB The title compds. [I; R1, R2 = H, halo, alkyl, etc.; R3 = H, halo, OH, etc.; R4 = H, halo, alkyl; or R3 and R4 together with the carbon atoms to which they are attached form a [N-alkylcarbonyl]pyrrolidin ring; R5 = alkyl; A = C, N; D = 5-10 membered aromatic ring which can contain up to 3 heteroatoms selected from the group consisting of N, O, or S], useful in medicaments, especially for the treatment of COPD, were prepared Thus, reacting

2-chloro-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]pyridine with 4-aminobenzamide afforded 18.5% II which showed IC50 of 0.13 μ M against p38 map kinase.

IT 459433-62-6P 459433-63-7P 459433-64-8P
 459433-65-9P 459433-66-0P 459433-67-1P
 459433-68-2P 459433-69-3P 459433-70-6P
 459433-71-7P 459433-72-8P 459433-73-9P
 459433-74-0P 459433-75-1P 459433-76-2P
 459433-77-3P 459433-78-4P 459433-79-5P
 459433-80-8P 459433-81-9P 459433-82-0P
 459433-83-1P 459433-84-2P 459433-85-3P
 459433-86-4P 459433-87-5P 459433-88-6P
 459433-89-7P 459433-90-0P 459433-91-1P
 459433-92-2P 459433-93-3P 459433-94-4P
 459433-95-5P 459433-96-6P 459433-97-7P
 459433-98-8P 459433-99-9P 459434-00-5P
 459434-01-6P 459434-02-7P 459434-03-8P
 459434-04-9P 459434-05-0P 459434-06-1P
 459434-07-2P 459434-08-3P 459434-09-4P
 459434-10-7P 459434-11-8P 459434-12-9P
 459434-13-0P 459434-14-1P 459434-15-2P
 459434-16-3P 459434-17-4P 459434-18-5P


459434-19-6P 459434-20-9P 459434-21-0P
 459434-22-1P 459434-23-2P 459434-24-3P
 459434-25-4P 459434-26-5P 459434-27-6P
 459446-72-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridinylpyrazoles for the treatment of COPD)


RN 459433-62-6 CAPLUS

CN Benamide, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-63-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-64-8 CAPLUS

CN Phenol, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-65-9 CAPLUS

CN 2-Pyridinamine, N-(2-methoxyphenyl)-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 459433-66-0 CAPLUS


CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 459433-67-1 CAPLUS

CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 459433-68-2 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 459433-69-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-70-6 CAPLUS

CN Acetamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459433-71-7 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-72-8 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-73-9 CAPLUS

CN 2-Pyridinamine, N-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 459433-74-0 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 459433-75-1 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-[4-(1H-1,2,3-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 459433-76-2 CAPLUS

CN Benzenesulfonamide, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-77-3 CAPLUS

CN Benzoic acid, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-78-4 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-79-5 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459433-80-8 CAPLUS

CN Benzamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-81-9 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 459433-82-0 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 459433-83-1 CAPLUS

CN Benzamide, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 459433-84-2 CAPLUS

CN Benzoic acid, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 459433-85-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 459433-86-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-87-5 CAPLUS

CN Benzenesulfonamide, 3-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-88-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-89-7 CAPLUS

CN Benzamide, 4-[[4-[3-(1-methylethyl)-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-90-0 CAPLUS

CN Benzamide, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-91-1 CAPLUS

CN Benzamide, N-methyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-92-2 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459433-93-3 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459433-94-4 CAPLUS

CN Benzenesulfonamide, 3-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-95-5 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(2-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459433-96-6 CAPLUS

CN Benzamide, N,N-dimethyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-97-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-[3-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-98-8 CAPLUS

CN Benamide, 4-[[4-[3-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459433-99-9 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-00-5 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-01-6 CAPLUS

CN Carbamic acid, [4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 459434-02-7 CAPLUS

CN Benzamide, 3-methyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-03-8 CAPLUS

CN Pyrrolidine, 1-[[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 459434-04-9 CAPLUS

CN Benzamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-05-0 CAPLUS

CN Carbamic acid, [4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 459434-06-1 CAPLUS

CN Benzoic acid, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-07-2 CAPLUS

CN Benzoic acid, 3-[[[3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-08-3 CAPLUS

CN Methanesulfonamide, N-[4-[[[4-[1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-09-4 CAPLUS

CN Benzenesulfonamide, 4-[[[4-[1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-10-7 CAPLUS

CN Benamide, 4-[[4-[1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-11-8 CAPLUS

CN 1,4-Benzenediamine, N-[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 459434-12-9 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-13-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-14-1 CAPLUS

CN 1,4-Benzenediamine, N-[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 459434-15-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 459434-16-3 CAPLUS

CN Benzamide, 4-[[4-[[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 459434-17-4 CAPLUS

CN Benzamide, 3-[[4-[[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-18-5 CAPLUS

CN Benzamide, 4-[[4-[[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 459434-19-6 CAPLUS

CN 1,4-Benzenediamine, N-[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 459434-20-9 CAPLUS

CN Benzamide, 3-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 459434-21-0 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[1-(7-fluoro-3-methylbenzo[b]thien-5-yl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-22-1 CAPLUS

CN Propanamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-23-2 CAPLUS

CN Ethanesulfonamide, N-(ethylsulfonyl)-N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-24-3 CAPLUS

CN Ethanesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-25-4 CAPLUS

CN Benzenesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-26-5 CAPLUS

CN 1-Propanesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 459434-27-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459446-72-1 CAPLUS


CN Benzenesulfonamide, 3-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



L27 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:688508 CAPLUS
 DN 137:232866
 TI 2-Aminopyridine and 2-pyridone C-nucleosides, oligonucleotides comprising, and tests using the same oligonucleotides
 IN Froehler, Brian C.; Gutierrez, Arnold J.; Matteucci, Mark D.
 PA Isis Pharmaceuticals, Inc., USA
 SO U.S., 18 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6447998	B1	20020910	US 1997-906378	19970805
	US 6495672	B1	20021217	US 2000-717422	20001121
	US 2003120065	A1	20030626	US 2002-171270	20020613
PRAI	US 1996-23241P	P	19960809		
	US 1997-906378	A3	19970805		
	US 2000-717422	A1	20001121		
AB	The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.				
IT	455944-68-0P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of 2-aminopyridine and 2-pyridone C-nucleosides, oligonucleotides comprising, and triplex binding capture)				
RN	455944-68-0 CAPLUS				
CN	D-erythro-Pentitol, 1-C-(2-amino-3,6-dimethyl-4-pyridinyl)-1,4-anhydro-2-deoxy-, (1R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:615603 CAPLUS
 DN 137:169514
 TI Preparation of pyrazoles as TGF- β inhibitors
 IN Gellibert, Francoise Jeanne
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062787	A1	20020815	WO 2002-GB424	20020131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1363904	A1	20031126	EP 2002-710136	20020131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004521901	T2	20040722	JP 2002-563140	20020131
	US 2004097502	A1	20040520	US 2003-470862	20030731
PRAI	GB 2001-2670	A	20010202		
	GB 2001-19399	A	20010809		
	WO 2002-GB424	W	20020131		

OS MARPAT 137:169514


AB The title compds. [I; R1 = H, alkyl, CH₂CONR₄R₅ (wherein R₄ = H, alkyl; R₅ = alkyl); R₂ = (un)substituted (CH₂)_nPh, (CH₂)_nheterocyclyl, (CH₂)_nheteroaryl; R₃ = H, halo, CN, etc.; n = 0-5; X, X₁ = CH, N, provided that X and X₁ are not both N], useful in therapy, particularly in the treatment of prophylaxis of disorders characterized by overexpression of transforming growth factor β (TGF- β), were prepared Thus reacting 4-{4-[3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]-(pyridin-2-yl)amino}phenol (preparation given) with 1-(2-chloroethyl)piperidine.HCl in the presence of Cs₂CO₃ in Me₂CO followed by trityl group removal afforded 49% I [R₁, R₃ = H; R₂ = 4-(2-piperidinoethoxy)phenyl]. All 28 exemplified compds. I showed IC₅₀ of 5 μ M or below in TGF- β assay, and IC₅₀ of 1 μ M or below against kinase Alk5.

IT 446880-51-9P 446880-52-0P 446880-53-1P
 446880-54-2P 446880-55-3P 446880-56-4P
 446880-57-5P 446880-58-6P 446880-59-7P
 446880-61-1P 446880-62-2P 446880-63-3P
 446880-64-4P 446880-65-5P 446880-66-6P
 446880-67-7P 446880-68-8P 446880-69-9P
 446880-70-2P 446880-71-3P 446880-72-4P
 446880-73-5P 446880-74-6P 446880-75-7P
 446880-76-8P 446880-77-9P 446880-78-0P
 446880-79-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazoles as TGF- β inhibitors)


RN 446880-51-9 CAPLUS

CN 2-Pyridinamine, N-(4-chlorophenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)

RN 446880-52-0 CAPLUS


CN 2-Pyridinamine, N-phenyl-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA
INDEX NAME)

RN 446880-53-1 CAPLUS

CN 2-Pyridinamine, N-(4-fluorophenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)


RN 446880-54-2 CAPLUS

CN 2-Pyridinamine, N-(2-furanylmethyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)




RN 446880-55-3 CAPLUS

CN 2-Pyridinamine, N-[3-(methoxysulfonyl)phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-56-4 CAPLUS

CN Benzonitrile, 3-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 446880-57-5 CAPLUS

CN Benzonitrile, 2-methoxy-4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 446880-58-6 CAPLUS

CN 2-Pyridinamine, N-[3-[2-(1-piperidinyl)ethoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-59-7 CAPLUS

CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 446880-61-1 CAPLUS

CN 2-Pyridinamine, N-(3-chlorophenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-62-2 CAPLUS

CN 2-Pyridinamine, N-(3-methylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)




RN 446880-63-3 CAPLUS

CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 446880-64-4 CAPLUS

CN 2-Pyridinamine, N-(3,4-dimethoxyphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-65-5 CAPLUS

CN 2-Pyridinamine, N-(4-chloro-3-methylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-66-6 CAPLUS

CN Benzonitrile, 2-chloro-5-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 446880-67-7 CAPLUS

CN Phenol, 4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 446880-68-8 CAPLUS

CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)




RN 446880-69-9 CAPLUS

CN 2-Pyridinamine, N-(4-methylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)




RN 446880-70-2 CAPLUS

CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 446880-71-3 CAPLUS

CN 2-Pyridinamine, N-(3,4-dimethylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
(9CI) (CA INDEX NAME)




RN 446880-72-4 CAPLUS

CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 446880-73-5 CAPLUS

CN 2-Pyridinamine, N-[3-(1-methylethoxy)phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-74-6 CAPLUS



CN 2-Pyridinamine, N-[4-(methoxysulfonyl)phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-75-7 CAPLUS

CN Benzonitrile, 2-methoxy-4-[[4-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 446880-76-8 CAPLUS

CN Morpholine, 4-[4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 446880-77-9 CAPLUS

CN Piperazine, 1-methyl-4-[4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 446880-78-0 CAPLUS

CN 2-Pyridinamine, N-[4-[2-(1-piperidinyl)ethoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-79-1 CAPLUS

CN 2-Pyridinamine, N-[3-[(1-methyl-1H-imidazol-2-yl)methoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



IT 446880-85-9P 446880-86-0P 446880-87-1P


446880-88-2P 446880-89-3P 446880-90-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazoles as TGF- β inhibitors)


RN 446880-85-9 CAPLUS

CN Benzoic acid, 4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 446880-86-0 CAPLUS

CN Benzoic acid, 4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 446880-87-1 CAPLUS

CN Phenol, 4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 446880-88-2 CAPLUS

CN 2-Pyridinamine, N-[4-(phenylmethoxy)phenyl]-4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 446880-89-3 CAPLUS

CN 2-Pyridinamine, N-(4-chlorophenyl)-4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-90-6 CAPLUS

CN Morpholine, 4-[4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzoyl]- (9CI) . (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:591913 CAPLUS

DN 137:150215

TI Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents

IN Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko

PA Banyu Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 194 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002220338	A2	20020809	JP 2001-18755	20010126
PRAI	JP 2001-18755		20010126		
OS	MARPAT 137:150215				

AB This invention relates to the general structures (I; Ar = N-containing hetero aromatic ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.


IT 322685-65-4 445430-71-7 445430-72-8
445430-73-9 445430-74-0 445430-77-3
445430-78-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)


RN 322685-65-4 CAPLUS

CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)




RN 445430-71-7 CAPLUS

CN Urea, N-[4-(4,5-dihydro-3-methyl-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)




RN 445430-72-8 CAPLUS

CN Urea, N-[4-(3-ethyl-4,5-dihydro-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)




RN 445430-73-9 CAPLUS

CN Urea, N-[4-(4,5-dihydro-3-propyl-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)




RN 445430-74-0 CAPLUS

CN Urea, N-[4-(4,5-dihydro-3-pentyl-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)




RN 445430-77-3 CAPLUS

CN Urea, N-[4-[4,5-dihydro-3-(hydroxymethyl)-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-78-4 CAPLUS

CN Urea, N-[4-(2-butyl-3-propyl-5-isoxazolidinyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L27 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:137207 CAPLUS

DN 134:178569

TI Preparation of as isoxazolylypyrimidines and related compounds as inhibitors of c-JUN N-terminal kinases and other protein kinases.

IN Green, Jeremy; Bemis, Guy; Grillot, Anne-Laure; Ledebouer, Mark; Salituro, Francis; Harrington, Edmund; Gao, Huai; Baker, Christopher; Cao, Jingrong; Hale, Michael

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012621	A1	20010222	WO 2000-US22445	20000811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2381882	AA	20010222	CA 2000-2381882	20000811
EP 1218369	A1	20020703	EP 2000-957485	20000811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000013551	A	20030617	BR 2000-13551	20000811
JP 2003531103	T2	20031021	JP 2001-517519	20000811
NO 2002000713	A	20020412	NO 2002-713	20020212
US 2003149051	A1	20030807	US 2002-74177	20020212
US 6693108	B2	20040217		
ZA 2002001248	A	20030220	ZA 2002-1248	20020213
US 2005026967	A1	20050203	US 2004-779532	20040213
PRAI US 1999-148795P	P	19990813		
US 1999-166922P	P	19991122		
US 2000-211517P	P	20000614		
WO 2000-US22445	W	20000811		
US 2002-74177	A3	20020212		

OS MARPAT 134:178569

AB Title compds. [I; XYZ = NOCR2, ON:CR2, N:NNR3, OC(R2):CR2, NN(R3)CR2; R1 = H, CONH2, TnR, TnAr2; R = (substituted) alipharyl; n = 0, 1; T = CO, CO2, CONH, SO2, SO2NH, COCH2, CH2; R2 = H, R, CH2OR, CH2OH, CHO, CH2SR, CH2SO2R, CH2NH2, CH2CN, (substituted) aryl, arylmethyl, heterocyclyl, heterocyclylmethyl, etc.; R3 = H, R, COR, CO2R, SO2R; G = R, Ar1; Ar1 = (substituted) (fused) aryl, aralkyl, heterocyclyl; Q = Q1, Q2; A = N, CR3; U = CR3, O, S, NR3; Ar2 = (substituted) (fused) aryl, heterocyclyl], were prepared. Thus, 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylamine (preparation given) was refluxed with PhBr, tris(dibenzylideneacetone)dipalladium, BINAP, and NaOCMe3 were refluxed together for 16 h to give 36% 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylphenylamine. Several I inhibited KNK3 at <0.1 μ M.

IT 326818-00-2P 326818-01-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of as isoxazolyipyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)


RN 326818-00-2 CAPLUS

CN 2-Pyridinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 326818-01-3 CAPLUS

CN 2-Pyridinamine, N-cyclohexyl-4-[3-(4-fluorophenyl)-5-(methoxymethyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



IT 326818-49-9 326818-52-4 326818-57-9

326818-58-0 326818-60-4 326818-62-6

326818-70-6 326818-73-9 326818-74-0

326818-98-8 326818-99-9 326819-00-5

326819-01-6 326819-32-3 326819-33-4


326819-34-5 326819-68-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of as isoxazolyipyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)


RN 326818-49-9 CAPLUS

CN 2-Pyridinamine, 4-(5-ethyl-3-phenyl-4-isoxazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-52-4 CAPLUS

CN Benzoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 326818-57-9 CAPLUS

CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-58-0 CAPLUS

CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-60-4 CAPLUS

CN Benzoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 326818-62-6 CAPLUS

CN Benzoic acid, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-70-6 CAPLUS

CN Ethanone, 1-[4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 326818-73-9 CAPLUS

CN Benzonitrile, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-74-0 CAPLUS

CN Benzonitrile, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 326818-98-8 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 326818-99-9 CAPLUS


CN 2-Pyridinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 326819-00-5 CAPLUS
 CN Acetamide, N-[3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 326819-01-6 CAPLUS
 CN 1,3-Benzenediamine, N-[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 326819-32-3 CAPLUS
 CN Benzenepropanoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-33-4 CAPLUS
 CN Benzeneacetic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 326819-34-5 CAPLUS


CN D-Valine, N-[3-[3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 326819-68-5 CAPLUS

CN 4-Morpholineethanamine, N-[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:78363 CAPLUS

DN 134:147614

TI Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)

IN Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko

PA Banyu Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 460 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2380389	AA	20010201	CA 2000-2380389	20000726
	JP 2001106673	A2	20010417	JP 2000-274175	20000726
	EP 1199306	A1	20020424	EP 2000-949909	20000726
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	JP 1999-211384	A	19990726		
	WO 2000-JP4991	W	20000726		

OS MARPAT 134:147614

AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic aromatic group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO₂; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = single bond, O, S, SO, SO₂, N-(un)substituted NH, SO₂NH, NHSO₂NH, NHSO₂, CONH, NHCO, NHCONH, NHCO₂, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepared. The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC₅₀ of 0.061 and 0.019 μ M against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 μ M, resp., for (\pm)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC₅₀ of 0.013 and 0.10 μ M, resp., vs. 0.15 and 0.87

μM , resp., for (+)-flavopiridol. Pharmaceutical formulations containing I were prepared

IT 322684-16-2P 322684-17-3P 322684-18-4P
 322684-19-5P 322684-20-8P 322684-21-9P
 322684-22-0P 322684-23-1P 322684-24-2P
 322684-25-3P 322684-32-2P 322684-33-3P
 322684-34-4P 322684-35-5P 322685-65-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(hetero)aryl-N'-heterocyclurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322684-16-2 CAPLUS

CN Urea, N-[4-[(5S)-4,5-dihydro-3-methyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-17-3 CAPLUS

CN Urea, N-[4-[(5R)-4,5-dihydro-3-methyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-18-4 CAPLUS

CN Urea, N-[4-[(5S)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-19-5 CAPLUS

CN Urea, N-[4-[(5R)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-20-8 CAPLUS

CN Urea, N-[4-[(5S)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-21-9 CAPLUS

CN Urea, N-[4-[(5R)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-22-0 CAPLUS

CN Urea, N-[4-[(5S)-4,5-dihydro-3-propyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-23-1 CAPLUS

CN Urea, N-[4-[(5R)-4,5-dihydro-3-propyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-24-2 CAPLUS

CN Urea, N-[4-[(5S)-4,5-dihydro-3-pentyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-25-3 CAPLUS

CN Urea, N-[4-[(5R)-4,5-dihydro-3-pentyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-32-2 CAPLUS

CN Urea, N-[4-[4,5-dihydro-3-(hydroxymethyl)-5-isoxazolyl]-2-pyridinyl]-N'-
[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 322684-33-3 CAPLUS

CN Urea, N-[4-[4,5-dihydro-3-(hydroxymethyl)-5-isoxazolyl]-2-pyridinyl]-N'-
[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 322684-34-4 CAPLUS

CN Urea, N-[4-(2-butyl-3-propyl-5-isoxazolidinyl)-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 322684-35-5 CAPLUS


CN Urea, N-[4-(2-butyl-3-propyl-5-isoxazolidinyl)-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322685-65-4 CAPLUS

CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:368337 CAPLUS

DN 133:4656

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 1210 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

Same as before


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6514977	B1	20030204	US 1998-196623	19981120
	CA 2351725	AA	20000602	CA 1999-2351725	19991117
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	EP 1144403	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9915420	A	20020122	BR 1999-15420	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	NZ 512344	A	20031128	NZ 1999-512344	19991117
	AU 774262	B2	20040624	AU 2000-21454	19991117
	AT 278685	E	20041015	AT 1999-965756	19991117
	US 6525059	B1	20030225	US 2000-513351	20000224
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
PRAI	US 1998-196623	A	19981120		
	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		
	WO 1999-US26007	W	19991117		
OS	MARPAT 133:4656				
AB	Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compound II. Data for biol. activity of I were given.				
IT	216504-83-5P 216504-84-6P 216504-85-7P 216504-86-8P 216504-87-9P 216504-88-0P 216505-92-9P 216506-33-1P 216506-39-7P				

216506-40-0P 216506-41-1P 216506-42-2P
 216506-64-8P 216506-65-9P 216506-66-0P
 216506-67-1P 216506-72-8P 216506-73-9P
 216506-82-0P 216506-83-1P 216506-85-3P
 216506-87-5P 216506-93-3P 216506-95-5P
 216506-96-6P 216506-98-8P 216506-99-9P
 216507-01-6P 216507-03-8P 216507-04-9P
 216507-06-1P 271574-67-5P 271574-81-3P
 271574-82-4P 271574-83-5P 271574-84-6P
 271574-85-7P 271574-86-8P 271574-87-9P
 271574-88-0P 271574-89-1P 271574-90-4P
 271574-91-5P 271574-93-7P 271574-96-0P
 271574-97-1P 271574-98-2P 271575-03-2P
 271575-04-3P 271575-05-4P 271575-07-6P
 271575-09-8P 271575-10-1P 271575-11-2P
 271575-12-3P 271575-21-4P 271575-22-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 216504-83-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)




RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)





RN 216504-85-7 CAPLUS
 CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)




RN 216504-86-8 CAPLUS
 CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-87-9 CAPLUS
 CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)

(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-88-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-92-9 CAPLUS
 CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 3 HCl


RN 216506-33-1 CAPLUS

CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-(9CI) (CA INDEX NAME)




RN 216506-39-7 CAPLUS

CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI) (CA INDEX NAME)




RN 216506-40-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-(9CI) (CA INDEX NAME)




RN 216506-41-1 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA
INDEX NAME)



RN 216506-64-8 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-
methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216506-65-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-66-0 CAPLUS


CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-67-1 CAPLUS


CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)

pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-72-8 CAPLUS

CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-73-9 CAPLUS


CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-82-0 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-

4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 216506-83-1 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 216506-85-3 CAPLUS

CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-87-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 216506-93-3 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-95-5 CAPLUS

CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-96-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 216506-98-8 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-99-9 CAPLUS

CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 216507-01-6 CAPLUS

CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 216507-03-8 CAPLUS

CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 216507-04-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)





RN 216507-06-1 CAPLUS

CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 271574-67-5 CAPLUS
 CN Carbamic acid, [3-[[5-(4-chlorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 271574-81-3 CAPLUS
 CN 1-Piperazinepropanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 271574-80-2
CMF C22 H27 F N6




CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 271574-82-4 CAPLUS
CN 1,2-Propanediol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 271574-83-5 CAPLUS
CN 1,3-Propanediamine, N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 271574-84-6 CAPLUS

CN 1,3-Propanediamine, N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 271574-85-7 CAPLUS

CN 2-Pyridinamine, N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 271574-86-8 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 271574-87-9 CAPLUS

CN 2-Pyridinamine, N-[(1-ethyl-4-piperidinyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-88-0 CAPLUS


CN 1,2-Ethanediamine, N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 271574-89-1 CAPLUS


CN 1-Pentanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271574-90-4 CAPLUS

CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 271574-91-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 271574-93-7 CAPLUS


CN 2-Pyridinamine, N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-96-0 CAPLUS

CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271574-97-1 CAPLUS

CN Benzenethanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271574-98-2 CAPLUS

CN Benzenepropanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 271575-03-2 CAPLUS


CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-04-3 CAPLUS


CN 1,4-Pentanediamine, N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl-, (9CI) (CA INDEX NAME)



RN 271575-05-4 CAPLUS


CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 271575-07-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(2-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 271575-09-8 CAPLUS

CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-10-1 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-11-2 CAPLUS


CN Benzeneethanol, β -[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-12-3 CAPLUS


CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-21-4 CAPLUS


CN Cyclohexanol, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 271575-22-5 CAPLUS

CN Cyclohexanone, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:736693 CAPLUS

DN 131:351324

TI Preparation of 1,5-diarylpyrazoles as p38 kinase inhibitors

IN Weier, Richard M.; Collins, Paul W.; Xu, Xiangdong; Crich, Joyce Z.; Rao, Shashidhar N.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 156 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958523	A1	19991118	WO 1999-US7036	19990512
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331878	AA	19991118	CA 1999-2331878	19990512
	AU 9938599	A1	19991129	AU 1999-38599	19990512
	EP 1077971	A1	20010228	EP 1999-921363	19990512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 6509361	B1	20030121	US 2001-674653	20010212
PRAI	US 1998-85494P	P	19980514		
	WO 1999-US7036	W	19990512		
OS	MARPAT 131:351324				
AB	Title compds. [I; R = H, halo, hydrocarbyl, CO ₂ H, etc.; R ₁ = H, N ₃ , hydrocarbyl(amino), aryl, etc.; R ₂ = H, N ₃ , (halo)hydrocarbyl, hydrocarbyloxy carbonyl, aryl, etc.; R ₃ = (un)substituted aryl; Z = N or CH] were prepared. Thus, 4-propionylpyridine was condensed with Me ₂ NCH(OMe) ₂ and the product cyclocondensed with 4-F-C ₆ H ₄ NHNH ₂ to give I (R = R ₁ = H, R ₂ = Me, R ₃ = C ₆ H ₄ F-4, Z = CH). Data for biol. activity of I were given.				
IT	250262-86-3P 250262-87-4P 250262-88-5P 250262-89-6P 250262-90-9P 250262-92-1P 250262-93-2P 250262-94-3P 250263-00-4P 250263-01-5P 250263-02-6P 250263-05-9P 250263-10-6P 250263-11-7P 250263-19-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 1,5-diarylpyrazoles as p38 kinase inhibitors)				
RN	250262-86-3 CAPLUS				
CN	Ethanol, 2-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)				




RN 250262-87-4 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 250262-88-5 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 250262-89-6 CAPLUS

CN 2-Pyridinamine, N-ethyl-4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 250262-90-9 CAPLUS

CN 2-Pyridinamine, N-methyl-4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-
(9CI) (CA INDEX NAME)




RN 250262-92-1 CAPLUS

CN Ethanol, 2-[[4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 250262-93-2 CAPLUS

CN 2-Pyridinamine, 4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 250262-94-3 CAPLUS

CN 2-Pyridinamine, 4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 250263-00-4 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 250263-01-5 CAPLUS

CN 2-Pyridinamine, 4-[1-(3-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 250263-02-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 250263-05-9 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 250263-10-6 CAPLUS

CN 2-Pyridinamine, 4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 250263-11-7 CAPLUS

CN 2-Pyridinamine, 4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 250263-19-5 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[1-(3-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:789144 CAPLUS

DN 130:38377

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.;
 Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.;
 Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier, Richard
 M.; Xu, Xiangdong

PA G.D. Searle and Co., USA; et al.

SO PCT Int. Appl., 828 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852940	A1	19981126	WO 1998-US10436	19980522
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2291115	AA	19981126	CA 1998-2291115	19980522
AU 9875883	A1	19981211	AU 1998-75883	19980522
AU 754830	B2	20021128		
ZA 9804358	A	19990524	ZA 1998-4358	19980522
EP 1000055	A1	20000517	EP 1998-923642	19980522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000235	T2	20000522	TR 2000-200000235	19980522
EE 9900527	A	20000615	EE 1999-527	19980522
BR 9809147	A	20000801	BR 1998-9147	19980522
JP 2002508754	T2	20020319	JP 1998-550650	19980522
NZ 501112	A	20021025	NZ 1998-501112	19980522
NO 9905695	A	20000121	NO 1999-5695	19991119
MX 9910759	A	20000531	MX 1999-10759	19991122
BG 64313	B1	20040930	BG 1999-103964	19991208
PRAI US 1997-47570P	P	19970522		
WO 1998-US10436	W	19980522		

OS MARPAT 130:38377

AB Title compds. [I; R1 = H, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compound II. Data for biol. activity of I were given.

IT 216504-83-5P 216504-84-6P 216504-85-7P
 216504-86-8P 216504-87-9P 216504-88-0P
 216505-92-9P 216506-33-1P 216506-39-7P
 216506-40-0P 216506-41-1P 216506-42-2P
 216506-64-8P 216506-65-9P 216506-66-0P
 216506-67-1P 216506-72-8P 216506-73-9P
 216506-82-0P 216506-83-1P 216506-85-3P
 216506-87-5P 216506-93-3P 216506-95-5P

216506-96-6P 216506-98-8P 216506-99-9P

216507-01-6P 216507-03-8P 216507-04-9P


216507-06-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylpyrazoles as p38 kinase inhibitors)


RN 216504-83-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)




RN 216504-84-6 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)





RN 216504-85-7 CAPLUS

CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)




RN 216504-86-8 CAPLUS
 CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-87-9 CAPLUS
 CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216504-88-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 216505-92-9 CAPLUS
 CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 3 HCl

RN 216506-33-1 CAPLUS
 CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 216506-39-7 CAPLUS

CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI)
(CA INDEX NAME)




RN 216506-40-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 216506-41-1 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)-
(9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS


CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 216506-64-8 CAPLUS


CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216506-65-9 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-66-0 CAPLUS

CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-67-1 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-72-8 CAPLUS

CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-73-9 CAPLUS

CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-82-0 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 216506-83-1 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 216506-85-3 CAPLUS

CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 216506-87-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 216506-93-3 CAPLUS

CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 216506-95-5 CAPLUS

CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 216506-96-6 CAPLUS

CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 216506-98-8 CAPLUS


CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-99-9 CAPLUS


CN Ethanol, 2-[[4-[[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)

RN 216507-01-6 CAPLUS

CN Ethanol, 2-[[4-[[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-
pyridinyl]amino]- (9CI) (CA INDEX NAME)


RN 216507-03-8 CAPLUS

CN 1-Propanol, 3-[[4-[[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)




RN 216507-04-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS


CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1993:191550 CAPLUS
 DN 118:191550
 TI Preparation an 2-aminopyridine-3-carbonitriles as human cytomegalovirus inhibitors
 IN Koeckritz, Peter; Ruhmann, Christiane; Fieblinger, Dagmar; Schroeder, Cornelia Dr; Joksche, Burkhardt; Heider, Harald; Weiher, Bettina; Liebscher, Juergen
 PA Berlin - Chemie AG, Germany
 SO Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4117802	A1	19921203	DE 1991-4117802	19910530
PRAI	DE 1991-4117802		19910530		
OS	MARPAT 118:191550				
AB	Title compds. [I; R1 = H, (cyclo)alkyl, phenylalkyl, aryl, heterocyclyl, etc.; R2 = H, alkyl, phenylalkyl, aryl; R3 = H, alkyl, aryl; R1R2, R2R3 = (benzo-condensed)alkylene] were prepared by cyclization of R4R5NCR3:CR2CR1:C(CN)2 (R4, R5 = C1-4 alkyl, cycloalkyl, PhCH2, Ph, or R4R5N = pyrrolidin-1-yl, piperidino, etc.) in the presence of NH3. I (R1 = 2-thienyl, R2 = R3 = H) had IC50 of 2.5 µmol/L against human cytomegalovirus in vitro.				
IT	146353-93-7P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as human cytomegalovirus inhibitor)				
RN	146353-93-7 CAPLUS				
CN	3-Pyridinecarbonitrile, 2-amino-4-(2-furanyl)- (9CI) (CA INDEX NAME)				



2 D 48

=> => d his

(FILE 'HOME' ENTERED AT 14:42:44 ON 24 FEB 2005)

FILE 'REGISTRY' ENTERED AT 14:43:05 ON 24 FEB 2005

L1 SCREEN 1839
 L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
 L3 STRUCTURE UPLOADED
 L4 QUE L3 AND L1 NOT L2
 L5 19 S L4 SSS SAM
 L6 SCREEN 1839
 L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
 L8 STRUCTURE UPLOADED
 L9 QUE L8 AND L6 NOT L7
 L10 50 S L9 SSS SAM
 L11 SCREEN 1839
 L12 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
 L13 STRUCTURE UPLOADED
 L14 QUE L13 AND L11 NOT L12
 L15 50 S L14 SSS SAM
 L16 SCREEN 1839
 L17 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
 L18 STRUCTURE UPLOADED
 L19 QUE L18 AND L16 NOT L17
 L20 9 S L19 SSS SAM
 L21 SCREEN 1839
 L22 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
 L23 STRUCTURE UPLOADED
 L24 QUE L23 AND L21 NOT L22
 L25 9 S L24 SSS SAM
 L26 359 S L24 SSS FUL

FILE 'CAPLUS' ENTERED AT 14:56:04 ON 24 FEB 2005

L27 19 S L26

FILE 'CAOLD' ENTERED AT 14:57:27 ON 24 FEB 2005

=> s 126

L28 0 L26

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.43

265.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-13.87

STN INTERNATIONAL LOGOFF AT 14:57:39 ON 24 FEB 2005